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Background: CD300-family molecules 
regulate innate immune responses. 
Results: We identified and characterized a 
novel immunoreceptor, CD300H. 
Conclusion: CD300H mediates neutrophil 
chemoattractants production. 
Significance: CD300H may play an important 
role in innate immunity.
3 
 
Abstract  
Recruitment of circulating monocytes and 
neutrophils to infection sites is essential for 
host defense against infections. Here, we 
identified a previously unannotated gene that 
encodes an immunoglobulin-like receptor, 
designated CD300H, and is located in the 
CD300 gene cluster. CD300H has a short 
cytoplasmic tail and associates with the 
signaling adaptor proteins, DAP12 and DAP10. 
CD300H is expressed on CD16+ monocytes 
and myeloid dendritic cells. Ligation of 
CD300H on CD16+ monocytes and myeloid 
dendritic cells with anti-CD300H monoclonal 
antibody induced the production of neutrophil 
chemoattractants. Interestingly, CD300H 
expression varied among healthy subjects, who 
could be classified into two groups according 
to “positive” and “negative” expression. 
Genomic sequence analysis revealed a 
single-nucleotide substitution [rs905709 
(G>A)] at a splice donor site on intron 1 on 
either one or both alleles. The international 
HapMap project database has demonstrated 
that homozygosity for the A allele of SNP 
rs905709 (“negative” expression) is highly 
frequent in Han Chinese in Beijing, Japanese in 
Tokyo, and Europeans (A/A genotype 
frequencies 0.349, 0.167, and 0.138 
respectively) but extremely rare in 
Sub-Saharan African populations. Together, 
these results suggest that CD300H may play an 
important role in innate immunity, at least in 
populations that carry the G/G or G/A 
genotype of CD300H. 
 
Introduction 
Recruitment of blood leukocytes to sites of 
infection is essential for host defense against 
infection. Circulating monocytes (Mo) and 
neutrophils are especially important effectors 
in the initiation of inflammatory responses to 
microbes (1). Mo in the human peripheral 
blood are divided into subsets on the basis of 
their cell-surface expression of CD14 and 
CD16 (2). A major subset with a phenotype of 
CD14+CD16– is referred to as classical or 
inflammatory Mo (iMo); these are similar to 
Ly6ChiCCR2hi Mo in mice (3). The CD16+ Mo 
subset can further be divided into two subsets, 
namely CD14+CD16+ and CD14dimCD16+, on 
the basis of CD14 expression (4). 
CD14dimCD16+ Mo resemble Ly6ClowCx3CR1hi 
Mo in mice and are referred to as patrolling Mo 
(pMo) (5-7). pMo crawl along the luminal side 
of the vascular endothelium in the steady state. 
CD14+CD16+ Mo are referred to as 
intermediate monocytes (intMo) and are found 
at low frequency (approximately 5% of blood 
monocytes) (8) in the peripheral blood; they 
represent a continuous transition from iMo 
(CD14+CD16–) to pMo (CD14dimCD16+) (7,9). 
iMo produce TNF-α,   IL-6, and IL-1 in 
response to bacteria-associated signals. In 
contrast, pMo respond poorly to bacterial 
components but potently to viruses and nucleic 
acids; they thus selectively detect viral 
infection and injury and produce inflammatory 
cytokines (4). In mice, Ly6Clow pMo provide 
immune surveillance and rapidly extravasate 
before neutrophils in response to Listeria 
monocytogenes infection (5). In addition, 
4 
 
activation of intravascular Ly6Clow pMo is 
responsible for neutrophil recruitment via 
TLR7-dependent CXCL1 production (6). 
However, the precise mechanism by which 
pMo produce chemokines—particularly in 
humans—remains unclear. 
CD300-family molecules are type 1 
immunoreceptors belonging to the 
immunoglobulin superfamily and are encoded 
by seven genes on human chromosome 17 and 
nine genes on mouse chromosome 11 (10,11). 
They are expressed on myeloid lineage cells, 
including monocytes–macrophages, 
granulocytes, dendritic cells, and mast cells, 
suggesting that they play an important role in 
innate immunity. CD300A (also named 
MAIR-I (12), LMIR1 (13), and CLM-8 (14) in 
mice) and CD300LF (MAIR-V (15,16), 
LMIR3 (17-20), and CLM-1 (21) in mice) 
mediate inhibitory signals via the 
immunoreceptor tyrosine-based inhibitory 
motif (ITIM) in their cytoplasmic regions. By 
contrast, CD300LB (LMIR5 (22)), CD300C, 
CD300LD (MAIR-IV (23), LMIR4 (17,24), 
and CLM-5 (25)), and CD300E have short 
cytoplasmic tails with no signaling motifs. 
However, CD300LB and CD300E each contain 
a positively charged lysine (K) residue, 
whereas CD300C and CD300LD contain a 
negatively charged glutamic acid (E) in their 
transmembrane domains (10) (11). These 
receptors noncovalently associated with 
membrane-bound signaling adaptor proteins, 
including DNAX adaptor protein 12 (DAP12), 
DAP10, and the γ  chain  of  the  Fc  receptor  for  
IgE (FcεRIγ) through interaction with a 
negatively charged amino acid [aspartic acid 
(D)] in the transmembrane domain of the 
adaptors and thus transmit activating signals 
(10,11). DAP12 and FcεRIγ contains ITAM in 
its cytoplasmic region, whereas DAP10 
contains  a YxxM motif, a potential src 
homology 2 (SH2) domain–binding site for the 
p85 regulatory subunit of the 
phosphatidylinositol (PI)3-kinase. Among the 
seven genes encoding human CD300 
molecules, those encoding CD300A, 
CD300LB, CD300C, CD300E, CD300LF, and 
CD300LG each have mouse homologs, as 
determined from their functional, molecular, 
and genetic characteristics (10,11). However, 
the mouse counterpart of human CD300LD 
and the human counterpart of mouse MAIR-II 
(CLM-4/LMIR2) and MAIR-VI 
(CLM-3/LIMR7) are unclear. 
 Here, we identified a previously 
unannotated gene encoding a novel molecule, 
designated CD300H, in the CD300 family gene 
cluster on human chromosome 17. We 
demonstrate that CD300H is expressed on 
CD14+CD16+ intMo and CD14dimCD16+ pMo 
and associates with DAP12 or DAP10. Upon 
crosslinking of CD300H on CD16+Mo and 
CD11c+ dendritic cell (DC), it mediates an 
activating signal for the production of 
neutrophil chemoattractants. 
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Experimental procedures 
Cloning of human CD300H cDNA 
Full-length cDNA of human CD300H was 
isolated from human CD14+ monocyte-derived 
cDNA by reverse transcription–polymerase 
chain reaction (RT-PCR) using 
CD300H-specific primers 
(5′-ATGACCCAGAGGGCTGGGGC-3′ and 
5′-TCATGACTCTGTCCAAGGAG-3′). 
 
Generation of Fc fusion protein 
Fusion proteins of the entire extracellular 
domains of CD300H, CD300A, and CD300C 
with the Fc portion of human immunoglobulin 
(Ig) G1 (CD300H-Fc, CD300A-Fc, and 
CD300C-Fc, respectively) were generated as 
described previously (26). 
 
Antibodies and flow cytometry analyses 
Monoclonal antibody (mAb) against CD300H 
(TX93; mouse IgG2a) was generated in our 
laboratory by immunizing mice with 
CD300H-Fc (12); mAb against CD300C 
(TX47; mouse IgG1) was generated by 
immunizing mice with BW5147 transfectant 
expressing CD300C, as described previously 
(12). MAb against CD300A and CD300C 
(TX49; mouse IgG1) was generated in our 
laboratory, as described previously (27). MAbs 
specific to human CD3 (clone UCHT1), CD14 
(clone M5E2), CD56 (clone B159), CD11c 
(clone B-ly6), CD16 (clone 3G8), HLA-DR 
(clone G46-6), CD40 (clone 5C3), CD80 
(clone BB1), and CD86 (clone 2331) were 
purchased from BD Biosciences (San Jose, 
CA). MAbs specific to human CD123 (clone 
AC145), CD203c (clone FR3-16A11), and 
CD304 (clone AD5-17F6) were purchased 
from Miltenyi Biotec (Auburn, CA). Flow 
cytometry analyses were performed with a 
FACS Fortessa flow cytometer (BD 
Biosciences). FlowJo software (Tree Star, 
Ashland, OR) was used for data analyses. 
 
Phylogenic analysis 
The protein sequences of human CD300-family 
molecules were aligned by using the ClustalW 
program (28). NJplot was used to construct tree 
diagrams (29).  
 
Cells and transfectants 
Murine T cell lines 2B4 and BW5147, human 
monocytic cell lines THP-1 and U937 and 
human embryonic kidney cell line 293T were 
used; they were cultured in RPMI1640 medium 
containing 5% fetal calf serum (FCS) except 
for 293T. 293T were cultured in DMEM 
containing 10% FBS. Blood samples were 
collected from healthy donors at the University 
of Tsukuba under an institutional review 
board–approved protocol. Written informed 
consent was obtained from the donors. Human 
peripheral blood mononuclear cells (PBMCs) 
were isolated from whole blood with 
LymphoPrep (Axis-Shield, Oslo, Norway) in 
accordance with the manufacturer’s protocol. 
CD16+ Mo were isolated from PBMCs by 
using the MACS cell separation system 
(Miltenyi Biotec): NK cells were depleted from 
the PBMCs by using anti-CD56 MicroBeads, 
and then CD16+ Mo were purified from the NK 
cell-depleted PBMCs by using anti-CD16 
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MicroBeads. The purity of the CD16+ Mo was 
more than 85%, as determined by flow 
cytometry. CD16- Mo were isolated from 
PBMCs by using the MACS cell separation 
system (Miltenyi Biotec): CD16+ cells were 
depleted from the PBMCs by using anti-CD16 
MicroBeads, and then CD16- Mo were purified 
from the CD16+ cell-depleted PBMCs by using 
anti-CD14 MicroBeads. The purity of the 
CD16- Mo was more than 90%, as determined 
by flow cytometry. CD11c+ dendritic cells 
(DCs) were isolated from PBMCs by using the 
Myeloid dendritic cell isolation kit (Miltenyi 
Biotec). The purity of the CD11c+ DC was 
more than 95%, as determined by flow 
cytometry. 2B4, U937, and BW5147 
transfectants stably expressing CD300H, 
CD300A, or CD300C tagged with Flag or HA 
at the N-terminus were established, as 
described previously (12). 293T transfectant 
transiently expressing Flag-tagged CD300Hs 
was established by using Lipofectamine 2000 
(Invitrogen, Carlsbad, CA). 
 
SNP genotyping 
Genomic DNA was extracted and purified 
from peripheral blood leukocyte using the 
QuickGene 610 L system (Fujifilm, Tokyo, 
Japan). Polymorphism was analyzed by 
genomic PCR with primer pairs 
5'-AAACCCAGAAGAGGCCAGAG-3' and 
5'-GGTTTGGACCTTGACTGTGC-3' and 
subsequent direct sequencing with the Big Dye 
Termination Kit (Applied Biosystems, Foster 
City, CA, USA). 
 
Biochemical analyses 
Cells were lysed in lysis buffer containing 1% 
NP-40 (Sigma-Aldrich, St. Louis, MO) or 
digitonin (Calbiochem, Damstadt, Germany) 
supplemented with protease inhibitors, as 
described previously (26). Cell lysates were 
immunoprecipitated with control Ig, anti-Flag 
mAb (M2; Sigma-Aldrich), anti-HA (3F10; 
Roche Applied Science, Mannheim, Germany), 
anti-DAP12 polyclonal antibody (FL-113; 
Santa Cruz Biotechnology, Santa Cruz, CA), 
anti-DAP10 (H-2; Santa Cruz Biotechnology) 
or anti-FcεRIγ-chain polyclonal antibody 
(06-727; Millipore, Billerica, MA). 
Immunoprecipitates were resolved by sodium 
dodecyl sulfate–polyacrylamide gel 
electrophoresis, transferred onto polyvinylidine 
fluoride membranes by electroblotting, and 
then immunoblotted with anti-Flag polyclonal 
antibody (F7425; Sigma-Aldrich), anti-HA 
(3F10; Roche Applied Science), anti-DAP12 
(FL-113; Santa Cruz Biotechnology), 
anti-DAP10 (H-2; Santa Cruz Biotechnology), 
or anti- FcεRIγ chain (T2040; US Biological) 
followed by horseradish peroxidase 
(HRP)-conjugated anti-rabbit IgG (eB182; 
eBioscience, San Diego, CA), anti-mouse IgG 
(eB144; eBioscience), or anti-rat IgG (NA935; 
GE Healthcare UK Limited, Buckinghamshire, 
UK). 
 
Stimulation of CD300H for cytokine and 
chemokine production 
CD16+ Mo (5 × 104 or 1 × 105/well), CD16- 
Mo, and CD11c+ DC (5 × 104 / well) were 
plated into 96-well flat-bottom plates precoated 
7 
 
with   10   μg/mL of F(ab′)2 fragments of either 
anti-CD300H (TX93) or control mouse IgG 
and cultured for 4 or 24 h at 37 C in 5% CO2. 
TNF-α   concentration in the culture 
supernatants were measured with ELISA kits 
purchased from BD Biosciences, 
concentrations of IL-12p70, TNF-α,   IL-10, 
IL-6, IL-1β  and  IL-8 in the culture supernatants 
were measured with BDTM cytometric bead 
array (BD Biosciences), and the mRNAs of IL6, 
CXCL1, CXCL2, CXCL5, and CXCL8 were 
quantified by real-time quantitative PCR. The 
sequences of the specific primers were: 
IL-6 forward, 
5′-GATGAGTACAAAAGTCCTGATCCA-3′, 
IL-6 reverse, 
5′-CTGCAGCCACTGGTTCTGT-3′;; 
CXCL1 forward, 
5′-TCCTGCATCCCCCATAGTTA-3′, 
CXCL-1 reverse, 
5′-CTTCAGGAACAGCCACCAGT-3′; 
CXCL2 forward, 
5′-CTTGTCTCAACCCCGCATCG-3′, 
CXCL2 reverse, 
5′-TCCTTCAGGAACAGCCACCA-3′; 
CXCL5 forward, 
5′-TTCGCCATAGGCCCACAGT-3′, 
CXCL5 reverse, 
5′-TTTCCATGCGTGCTCATTTCTC-3′; and 
CXCL8 forward, 
5′-AGACAGCAGAGCACACAAGC-3′, 
CXCL8 reverse, 
5′-CACAGTGAGATGGTTCCTTCC-3′. 
 
cDNA synthesis and RT-PCR 
Total RNA was extracted with Isogen reagent 
(Nippon Gene, Tokyo, Japan), and cDNA was 
synthesized by using a High-Capacity 
RNA-to-cDNA Kit (Applied Biosystems, 
Foster City, CA, USA). Real-time RT-PCR was 
performed with SYBR Green master mix 
(Applied Biosystems). Expression of each 
target gene was normalized against that of 
GAPDH (primer sequences 
5′-CTTCACCACCATGGAGAAGGC-3′ and 
5′-GGCATGGACTGTGGTCATGAG-3′).  
 
Neutrophil migration assay 
Neutrophils were isolated from whole blood 
with Polymorphprep (Axis-Shield) in 
accordance with the manufacturer’s protocol. 
Supernatant obtained from TX93-stimulated 
CD16+ Mo was added to the lower 
compartment of 96-well Transwell plates (pore 
size 3.0 μm; Corning, New York, USA) at a 
total  volume  of  235  μL per well. Neutrophils (1 
× 105) were placed in the upper compartment at 
a total volume of 75 μL, and then the plates 
were incubated for 30 min at 37 C in 5% CO2. 
Cells in the lower compartment were collected 
and counted by using a Guava easyCyte Mini 
flow cytometer (Millipore). 
 
Statistical analyses 
The unpaired Student’s t-test was used for 
statistical analyses. P values of less than 0.05 
were considered statistically significant. All 
statistical analyses were carried out using 
GraphPad Prism 5.0c software (GraphPad 
Software, San Diego, CA, USA).   
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Results 
Cloning of the gene encoding human 
CD300H 
In our search for a human homolog of MAIR-II 
in the National Center for Biotechnology 
Information database, we found a previously 
unannotated gene located in the human CD300 
gene cluster on chromosome 17 (Figure 1A). 
We isolated full-length cDNA from human 
CD14+ Mo-derived cDNA by RT-PCR. 
Sequence analysis revealed that an open 
reading frame of 603 bp encoded a type I 
transmembrane receptor, which contained a 
20-amino-acid (aa) leader sequence, a 148-aa 
extracellular region containing an Ig-like 
domain, a 23-aa transmembrane region, and a 
10-aa cytoplasmic domain with no signaling 
motif (Figure 1B). The Ig-like domain 
contained a potential N-glycosylation site. The 
transmembrane domain contained a positively 
charged lysine residue (Figure 1C). Because 
this homolog was the eighth member of the 
human CD300 family of receptors, we termed 
it CD300H. We also identified a splicing 
variant that lacked a transmembrane domain; 
we called this variant CD300Hs (Figure 1B, C). 
A database search demonstrated that CD300H 
had 44% amino acid identity with mouse 
MAIR-II/CLM-4/LMIR2 and CD300c/CLM-6, 
but it had lower rates of identity with 
CD300e/CLM-2/LMIR6 (42%), 
CLM-3/LMIR7 (35%), 
CD300ld/CLM-5/LMIR4 (40%), 
CD300lb/CLM-7/LMIR5 (35%), and 
CD300lg/CLM-9 (35%) among the 
non-ITIM-bearing receptors. The gene 
encoding CD300H was located between 
CD300C and CD300LD on human 
chromosome 17q25.1 (Figure 1A). We 
analyzed the degree of identity of the 
extracellular Ig domain of CD300H with the 
sequences of CD300 family members and 
constructed a molecular phylogenetic tree by 
using ClustalW2 phylogeny. The Ig-like 
domains of CD300A and CD300C had the 
greatest identity (53%) with that of CD300H; 
other members of the family had lower identity 
levels (Figure 1D). 
 
Expression of CD300H 
To investigate the cellular distribution of 
CD300H, we generated a mAb against 
CD300H (clone TX93) and analyzed its 
specificity. TX47 and TX49 were previously 
generated mAbs against CD300C, and 
CD300A and CD300C, respectively (Figure 2B 
and C) (27). Although CD300H had a high 
level of identity with CD300A and CD300C, 
TX93 mAb bound specifically to 
CD300H-expressing THP-1 and 2B4 
transfectants but not to CD300A- or 
CD300C-expressing BW5147 transfectants 
(Figure 2A and B). In addition, TX93 mAb 
bound to CD300H-Fc fusion protein but not to 
CD300A-Fc or CD300C-Fc protein (Figure 
2C). These results indicated that TX93 mAb 
specifically recognized CD300H. 
 Flow cytometry analyses of human 
peripheral blood cells demonstrated that 
CD300H was expressed on myeloid lineage 
cells, including CD16+ Mo (Figure 3E and H) 
and myeloid DCs (n=9, Figure 3C and H) but 
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not on plasmacytoid DCs (n=3, Figure 3D). By 
contrast, CD300H was not expressed on 
lymphocytes (T cells, B cells, and NK cells) 
(n=3 in each, Figure 3A and B) or granulocytes 
(eosinophils, neutrophils, and basophils) (n=3 
in each, Figure 3F and G). CD16+ Mo can be 
divided into two subsets (namely 
CD14dimCD16+ and CD14+CD16+ Mo) (4) on 
the basis of their CD14 expression; mean 
fluorescence intensity (MFI) of CD300H 
expression was comparable between these 
subsets (p=0.5816, n=13 in each, Figure 3E 
and H). Compared to CD14dimCD16+ and 
CD14+CD16+ Mo, CD16- Mo (n=13) exhibited 
significantly low-level of CD300H expression 
(p=0.0234 and p=0.0270, respectively, Figure 
3E and H).  
 
Individual differences in CD300H expression 
Genomic DNA database analysis demonstrated 
that CD300H consisted of four exons (Figure 
4A), but the gene encoding CD300Hs lacked 
exon 3, which encoded the transmembrane 
region. Interestingly, we observed that 4 out of 
the 13 individuals examined in Figure 3 
showed no detectable expression of CD300H 
on CD16+ Mo (open circle, Figure 3H). 
Genomic DNA analyses of these individuals 
demonstrated a single-nucleotide substitution 
(rs905709; G>A) of CD300H, that abolished 
the intron 1 donor splice site (Figure 4A). This 
can lead to loss of CD300H transcript 
expression through the action of nonsense–
mediated mRNA decay machinery (30). Indeed, 
persons carrying the rs905709 A/A genotype 
showed a loss of CD300H transcripts (Figure 
4B) and protein (Figure 3H and 4C). In 
contrast, CD16+ Mo derived from subjects with 
G/A or G/G genotype expressed the CD300H 
transcript (Figure 4B) and protein on their cell 
surfaces (Figure 3H and 4C). The A/A 
genotype frequency of rs905709 differed 
significantly in the different ethnic populations 
and is observed at high frequency in Han 
Chinese in Beijing, China (HCB), Japanese in 
Tokyo, Japan (JPT) and CEPH (Utah Residents 
with Northern and Western European Ancestry, 
CEU) (A/A genotype frequencies 0.349, 0.167, 
and 0.138, respectively). However, it is 
extremely rare in Yoruba in Ibadan, Nigeria 
(YRI) (Figure 4D) (31). 
 
CD300H associates with DAP12 and DAP10 
in U937 cells 
To analyze the biochemical characteristics of 
CD300H, we generated a BW5147 transfectant 
stably expressing Flag-tagged CD300H at the 
N-terminus. Immunoprecipitation of CD300H 
protein from lysates of BW5147 transfectant 
and subsequent immunoblotting with anti-Flag 
antibody revealed that human CD300H had a 
molecular weight of ~25 kDa under reducing 
conditions and ~50 kDa under non-reducing 
conditions (Figure 5A), suggesting that 
CD300H forms dimer formation. To determine 
whether CD300H forms homodimeric or 
hetreodimeric structure, we generated BW5147 
transfectant simultaneously expressing 
Flag-tagged and hemagglutinin (HA)-tagged 
CD300H and performed 
co-immunoprecipitation assay. We found that 
HA-tagged CD300H was not 
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co-immunoprecipitated with Flag-tagged 
CD300H and vice versa (Figure 5B), 
suggesting that CD300H forms heterodimeric 
structure with an undetermined molecule with 
a molecular weight of ~25 kDa expressed in 
BW5147 cells.  
 Next, we analyzed to determine 
whether CD300Hs is a secreted form of 
CD300H. We performed immunoblot analysis 
of culture supernatant of 293T transfectant 
transiently expressing CD300Hs tagged with 
flag at the N-terminus and found that CD300Hs 
was a secreted form of CD300H (Figure 5C). 
CD300H possesses a lysine residue in 
the transmembrane region, suggesting that 
CD300H associates with DAP12, DAP10 
and/or FcεRIγ  chain.  We found that flag-tagged 
CD300H was co-immunoprecipitated with 
endogenous DAP12 and DAP10, and vice 
versa, but not with FcεRIγ  chain, in U937 cells 
(Figure 5D). This result indicates that, unlike 
mouse MAIR-II, CD300H associates with 
DAP12 but not with the FcεRIγ  chain in U937 
cells. 
 
CD300H transduces an activating signal in 
CD16+ Mo 
Our findings that CD300H was expressed on 
CD16+ Mo and was associated with DAP12 
and DAP10 in U937 cell line suggested that 
CD300H was an activating receptor on CD16+ 
Mo. Human CD16+ Mo consists of two distinct 
subsets. CD14dimCD16+ Mo resemble murine 
Ly6Clow Mo (5), which are called as pMo and 
produce chemokines. On the other hand, 
CD14+CD16+ Mo are described as intMo (32), 
main producers of inflammatory cytokines 
such as TNF-α and IL-1β (33).  Therefore, we 
investigated whether CD300H mediated 
signaling for inflammatory cytokine and 
chemokines production in CD16+ Mo. We 
sorted CD16+ Mo from the PBMCs of healthy 
donors with the G/G (CD300H+) or A/A 
genotype (CD300H–) and then stimulated them 
with plate-coated F(ab′)2 fragments of TX93 
mAb or control Ig (Figure 6A and B). 
Stimulation of CD300H+ CD16+ Mo with 
TX93 mAb induced significantly more TNF-α 
and IL-6 production than did stimulation with 
control Ig. In contrast, stimulation with TX93 
mAb did not increase cytokine production by 
CD300H– CD16+ Mo compared with 
stimulation with control Ig (Figure 6B and C). 
Thus CD300H transduces an activating signal 
for cytokine production in CD16+ Mo. A recent 
study has demonstrated that murine Ly6Clow 
Mo recruit neutrophils in a TLR7-dependent 
manner to mediate focal necrosis of endothelial 
cells (6). CD16+ Mo produce chemoattractants 
for neutrophils. To examine whether CD300H 
is involved in this process, CD16+ Mo were 
stimulated with plate-coated F(ab′)2 fragments 
of TX93 mAb or control Ig for 24 h; the culture 
supernatant was then plated in the lower 
compartment of a Transwell, and neutrophils 
derived from the peripheral blood were added 
to the upper compartment. In the case of 
CD300H+CD16+ Mo but not CD300H-CD16+ 
Mo, the average number of neutrophils that 
migrated from the upper to the lower 
compartment upon TX93 mAb stimulation was 
significantly greater than that with control 
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Ig-stimulated culture supernatant 
(approximately 1.3-fold increase, p < 0.05) 
(Figure 6D). These results suggested that 
CD300H mediated a signal for the production 
of a neutrophil chemoattractant. Indeed, the 
expression of CXCL8, CXCL1, CXCL2, and 
CXCL5, which encode chemokines for 
neutrophil attraction, was significantly greater 
in CD300H+ Mo, but not CD300H– Mo, than in 
the controls after stimulation with plate-coated 
F(ab′)2 fragments of TX93 mAb (Figure 6E).  
 
CD300H had no effect on IL-8 production in 
CD16- Mo 
Since CD16- Mo also expresses CD300H 
(Figure 3E), we analyzed the CD300H activity 
on CD16-CD14+ classical Mo sorted from the 
peripheral blood from donors with G/G- 
(CD300H+) or A/A-genotype (CD300H-). We 
analyzed the production of cytokines, including 
CXCL8 (IL-8), IL-12p70, TNF-α, IL-10, IL-6, 
and IL-1β after stimulation with anti-CD300H 
mAb by using cytometric bead array (CBA). 
However, we could not detect a significant 
amount of cytokines except IL-8 and observed 
no significant differences in IL-8 production 
between stimulation with control antibody and 
anti-CD300 mAb (Figure 6F and G). This 
might be resulted from the low level of 
CD300H expression on CD16- Mo compared 
with CD16+ Mo. 
 
CD300H transduces an activating signal in 
CD11c+ DC 
CD11c+ DC also express CD300H at 
comparable level to CD16+ Mo. We addressed 
whether CD300H transduces activating signal 
in CD11c+ DC. We purified CD11c+ cells by 
MACS sorting system (Fig. 7A), stimulated 
them with plate-coated F(ab’)2 fragment of 
TX93 mAb and analyzed surface expression of 
co-stimulatory molecules and cytokines 
production by flow cytometry. We found that 
TX93 stimulation did not enhance the 
expression level of co-stimulatory molecules, 
such as CD40, CD86, CD80, and HLA-DR on 
G/G-genotype (CD300H+)-derived CD11c+ DC 
(Figure 7B). However, CD11c+ DC from 
G/G-genotype, but not A/A-genotype 
(CD300H-), produced IL-8 upon CD300H 
stimulation (Fig. 7C). These results indicate 
that CD300H induced IL-8 production by 
CD16+ Mo and CD11c+ DC and may contribute 
to neutrophil attraction.
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Discussion 
We identified and characterized a new member of 
the human CD300 family of immunoreceptors, 
which we designated CD300H. It is expressed on 
CD14+CD16+ intMo and CD14dimCD16+ pMo in 
the peripheral blood and transduces an activating 
signal for the production of inflammatory 
cytokines (TNF-α and IL-6) and chemokines 
(CXCL1, CXCL2, CXCL5, and  IL-8) by 
CD16+ Mo. In addition, CD300H induces IL-8 
production by CD11c+ DC. Importantly, we 
demonstrated that CD300H mediates neutrophil 
recruitment through the production of 
chemoattractants for those cells, suggesting that 
CD300H plays an important role in host 
immunity against bacterial and viral infections. 
Despite recent progress in human Mo 
studies, the physiological roles of CD16+ Mo 
have not been fully elucidated. One recent report 
described a healthy family with CD16+ Mo 
deficiency in the blood (34), suggesting that that 
the function of CD16+ Mo is redundant. In 
accordance with this idea, we also found a 
subpopulation of healthy people whose CD16+ 
Mo did not express CD300H, suggesting that 
CD300H on CD16+ Mo is functionally redundant. 
However, because CD16+ pMo are implicated in 
inflammatory diseases such as arthritis and 
atherosclerosis (35-37) or autoimmune diseases 
such as SLE (4), deficiency of CD16+ pMo or 
CD300H on CD16+ pMo might be potentially 
advantageous, rather than disadvantageous, for 
maintaining homeostasis. The genetic mutation 
known as CCR5-delta 32 is a well-studied 
example of an advantageous allele with a 
well-characterized geographic distribution. This 
mutation plays an important role in human 
immunodeficiency virus (HIV)-1 resistance 
because it prevents functional expression of the 
CCR5 chemokine receptor, the entry receptor for 
HIV-1 (38). The mutation is found principally in 
Europe and Western Asia, where average 
frequencies are approximately 10%, but not in 
Western and Central Africa (38). The mutant 
allele, which can be regarded as a natural 
knockout in humans, is not accompanied by an 
obvious phenotype in homozygous individuals, 
although CCR5 has a protective role against 
Listeria monocytogenes infection in mice (39). 
Additional studies are required to determine the 
functional role of CD300H in immunity and 
inflammation. 
CD300H has a splicing variant, 
CD300Hs, which lack the transmembrane domain. 
We found that CD300Hs is a secreted form of 
CD300H. Recent findings demonstrated that 
activating immunoglobulin-like receptors 
CD300b and Triggering receptor expressed on 
myeloid cells (TREM-1) also produce soluble 
forms sCD300b and sTREM-1, respectively, by 
proteolytic cleavage (40,41). While sCD300b 
amplifies LPS-induced inflammation (40,42), 
sTREM-1 attenuates excessive inflammatory 
response by counterregulating TREM-1 (41) 
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probably by acting as a decoy receptor, as 
observed in the TNF-α system (43). Therefore, 
expression of CD300Hs may modulate CD300H–
mediated inflammatory responses in vivo.  
Our studies suggested that CD300H 
may form a heterodimeric structure in mouse T 
cell lymphoma, BW5147. Recent evidences 
demonstrated that CD300C forms either 
homodimer or heterodimer with all CD300 
family members. Although these dimer formation 
requires immunoglobulin (Ig)-like domains, 
CD300C did not bind other Ig-like receptors, 
such as TREM-1 and CD28 (44) (45). The Ig-like 
domain of CD300H has 53% homology to that of 
CD300C, suggesting that CD300H may also form 
heterodimer with mouse CD300 family members 
expressed on BW5147 cell line. Since we did not 
detect surface expression of mouse CD300a, 
MAIR-II and CD300lf on BW5147 cells by flow 
cytometry using TX41(12), TX52 (46), and TX70 
(15) mAbs, respectively (data not shown), 
CD300H may interact with mouse CD300 family 
members other than these Ig-like receptors. 
Unlike CD300C, CD300H has a 
positively-charged lysine residue in its 
transmembrane region and interact with DAP12 
and DAP10. Thus, CD300H may be able to 
mediate an activating signal upon ligand binding. 
However, the heterodimer of CD300H with other 
CD300 receptors may positively or negatively 
modulate the signaling.  
To elucidate the physiological roles of 
CD300H on CD16+ pMo in vivo, the counterpart 
of CD300H in mice needs to be identified. 
Although we identified CD300H in our search for 
a human homolog of MAIR-II, there are several 
differences between MAIR-II and CD300H. First, 
MAIR-II inhibits B-cell receptor–mediated 
signaling in B cells (47), whereas CD300H 
expression on human peripheral blood B cells 
was not detected by flow cytometry using TX93 
mAb (Figure 3). Second, MAIR-II is a unique 
receptor that binds to either DAP12 or FcεRIγ; 
however, CD300H did not show an association 
with FcεRIγ in U937 cells. Third, CD300H is 
located adjacent to CD300C on human 
chromosome 17, whereas 
Cd300ld/MAIR-IV/LMIR4/Clm-5, but not 
MAIR-II, is located adjacent to Cd300c on mouse 
chromosome 11. Recent studies have 
demonstrated that CD300 family receptors 
recognize lipids such as phosphatidylserine (PS), 
ceramide, and lipoprotein as ligands that mediate 
signals in mast cells and macrophages via these 
receptors (48-50). We and others reported that 
human CD300A binds to PS and 
phosphatidylethanolamine (PE) (11,27,50). 
Because CD300H has high amino acid identity 
with CD300A, we assessed whether CD300H 
also bind to PS and PE by dot blot analyses using 
a lipid-bound membrane. However, CD300H 
bound to neither PS nor PE (data not shown). 
Future studies are required for identification of a 
ligand for CD300H to understand the function of 
CD300H in vitro and in vivo.
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Figure Legends 
Figure 1. Molecular characteristics of CD300H. (A) Localization on mouse and human 
CD300 family gene maps. Mouse and human family genes are mapped on chromosomes 11 
and 17, respectively. (B) Amino acid sequences of CD300H and CD300Hs. Numbers in 
parentheses (left margin) indicate amino acid (aa) positions; underlines indicate putative leader 
and transmembrane sequences; circles denote potential N-linked glycosylation sites in the 
extracellular domain and the charged aa residue in the transmembrane region; * indicates 
cysteine residues potentially involved in disulfide bonding of the immunoglobulin-like 
domains. (C) Schematic diagram of CD300H (left) and CD300Hs (right) proteins. The pair of 
cysteine residues in the extracellular portion is potentially able to participate in intra-chain 
disulfide bonding for the formation of Ig-like domains. (D) Phylogenetic tree showing the 
relationships among the Ig-like-domain amino acid sequences of human CD300 molecules. 
Each neighbor-joining phylogenetic tree was generated by aligning the translated sequences of 
the open reading frames for CD300 proteins by using the ClustalW algorithm. 
 
Figure 2. Characterization of the anti-CD300H monoclonal antibody, TX93. (A) Flow 
cytometry of THP-1 cells or THP-1 transfectants expressing CD300H (5 × 105 cells per 
experiment) were stained with biotinylated control mouse immunoglobulin (shaded) or 
anti-CD300H (TX93) (thick lines) followed by allophycocyanin-conjugated streptavidin. (B) 
Flow cytometry of BW5147 transfectants expressing CD300A or CD300C or 2B4 transfectants 
expressing CD300H (5 × 105 cells per experiment) were stained with control mouse 
immunoglobulin (shaded), TX93, anti-CD300C (TX47), or anti-CD300A and CD300C (TX49) 
(thick lines), followed by phycoerythrin-conjugated  goat  F(ab′)2 fragment anti-mouse IgG. (C) 
Microtiter plates coated with control human IgG, CD300H-Fc, CD300A-Fc, or CD300C-Fc 
were incubated with control mouse IgG, TX93, TX47, or TX49, and binding was analyzed by 
ELISA. Data are representative of two independent experiments. 
 
Figure 3. Expression of human CD300H protein. (A-G) Flow cytometry of peripheral blood 
mononuclear cells (5 × 105 cells per experiment) from healthy donors. Cells were stained with 
specific antibodies to distinguish different cell subsets and simultaneously stained with 
biotinylated control mouse immunoglobulin (shaded) or anti-CD300H (TX93) (thick lines), 
followed by PE/Cy-7 streptavidin. PI positive dead cells were excluded. Cells in outlined areas 
were gated and analyzed for CD300H expression. Cells in (C) are Lineage (CD3, CD19, CD56, 
CD14)-. Cells in (E) are Lineage (CD3, CD19, CD56)- HLA-DR+. HLA-DR, human leucocyte 
antigen-DR; FSC-A, forward scatter-area; B, B cell; T, T cell; NK, natural killer cell; mDC, 
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myeloid dendritic cell; pDC, plasmacytoid dendritic cell; Eos, eosinophil; Neu, neutrophil; 
Baso, basophil. Data are representative of at least three independent experiments. (H) The 
mean fluorescence intensity (MFI) of CD300H expression on each cell type from each 
individual carrying A/A (circle), G/A (triangle), or G/G (square) genotype is shown. ΔMFI: 
MFI of stained with isotype control was subtracted from MFI of CD300H stained with 
anti-CD300H (TX93). *P < 0.05; NS, not significant. 
 
Figure 4. A single-nucleotide polymorphism, rs905709 (allele A), at the splice donor site on 
intron 1 of CD300H is responsible for the loss of CD300H expression. (A) Schematic 
structure of the exon-intron of CD300H. F and R are the sites of primers. Peripheral blood 
mononuclear cells derived from healthy donors carrying the A/A, G/A, or G/G genotype were 
subjected to RT-PCR analysis for the expression of CD300H and GAPDH transcripts (B) or 
were analyzed for surface expression of CD300H on CD14dimCD16+ Mo by flow cytometry 
analysis (C), as described in the caption to Figure 3. Data are representative of two independent 
experiments. (D) Table from the National Center for Biotechnology Information single 
nucleotide polymorphism (SNP) web site showing the population diversity of SNP rs905709 in 
Utah residents with ancestry from Northern and Western Europe (CEU), Han Chinese in Beijing 
(HCB), Japanese in Tokyo (JPT), and Yoruba in Ibadan, Nigeria (YRI) populations. HWP, 
Hardy-Weinberg probability; Chrom. Sample Cnt, chromosome sample count; IG, individual 
genotype. 
 
Figure 5. Biochemical analyses of CD300H. (A) BW5147 cells and transfectants expressing 
Flag-tagged CD300H (5 × 106 cells per experiment) were lysed in 1% NP-40 buffer, 
immunoprecipitated with anti-Flag, and immunoblotted with anti-Flag. (B) BW5147 
transfectants simultaneously expressing Flag-CD300H and HA-CD300H were lysed in 
digitonin buffer, immunoprecipitated with anti-HA or anti-Flag, and immunoblotted with 
anti-HA or anti-Flag in reducing condition. (C) Culture supernatant from 293T cells transiently 
expressing Flag-tagged CD300Hs or mock were immunoprecipitated with anti-Flag and 
immunoblotted with anti-Flag. (D) U937 cells and transfectants stably expressing Flag-tagged 
CD300H were lysed in digitonin buffer, immunoprecipitated with anti-Flag, anti-DAP12, 
anti-DAP10, or anti-FcεRIγ,  and  immunoblotted with anti-DAP12, anti-DAP10, or anti-FcεRIγ. 
Data are representative of two independent experiments. 
 
Figure 6. CD300H ligation in CD16+ monocytes (Mo) induces cytokine and chemokine 
secretion. CD16+ Mo (A-E) and CD16- Mo (F, G) were isolated from peripheral blood 
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mononuclear cells by using the MACS system. Their purity was then analyzed by using flow 
cytometry (A, F). MACS-isolated Mo from G/G (CD300H+) or A/A (CD300H-) genotype 
donors were stimulated with plate-coated  F(ab′)2 fragment of TX93 or control Ig for 24 h (B, D, 
G) or 4 h (C, E). Culture supernatant was analyzed by ELISA (B), subjected to neutrophil 
migration assay (D), or cytometric bead array (G). Cells were analyzed for IL-6 (C) and 
chemokines (E) expression by using quantitative polymerase chain reaction. In (D), culture 
supernatant was transferred to the lower compartment of Transwells, and neutrophils were 
placed in the upper compartment. This was followed by a 30-min incubation. *P < 0.05; **P < 
0.01; ***P < 0.001; NS, not significant. All data are representative of three independent 
experiments. Data in (C) and (E) are shown as mean ± SD of four (CD300H+) and three 
(CD300H-) different donors. 
 
Figure 7. CD300H ligation in CD11c+ dendritic cell (DC) induces IL-8 production. 
CD11c+ DC were isolated from peripheral blood mononuclear cells by using the MACS 
system. (A) The purity was analyzed by using flow cytometry. MACS-isolated DC from G/G 
(CD300H+) or A/A (CD300H-) genotype donors were stimulated with plate-coated   F(ab′)2 
fragment of TX93 or control Ig for 24 h. (B) Cells were analyzed for expression of 
co-stimulatory molecules by flow cytometry. (C) Culture supernatant was analyzed by 
cytometric bead array. Lineage: CD3, CD19, CD56, CD14. **P < 0.01; NS, not significant. 
Data are representative of three independent experiments.  
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